Edwards Lifesciences Eyes TAVR Growth Surge with Label Expansion in 2025

Edwards Lifesciences closed 2024 with stronger-than-expected fourth-quarter sales, primarily driven by its TAVR devices, despite earlier hospital capacity constraints. Company executives are optimistic that these constraints will ease, supported by hospitals investing in structural heart programs. An anticipated midyear FDA approval for expanded use of the Sapien TAVR platform in asymptomatic severe aortic stenosis patients is expected to drive further sales growth. Recent study data reinforcing the benefits of early intervention could lead to shifts in the standard of care, increasing adoption of the technology.

Looking ahead, Edwards projects TAVR sales growth of 5% to 7% in 2025, with stronger momentum expected in the second half of the year. While seasonal slowdowns in patient screening may impact first-quarter performance, analysts see long-term potential in the company’s structural heart pipeline. CEO Bernard Zovighian reaffirmed the company’s goal of achieving 10% annual sales growth on average, emphasizing the role of innovative heart valve technologies in driving future expansion.